Curis, Inc. (CRIS)
| Market Cap | 23.27M |
| Revenue (ttm) | 9.44M |
| Net Income (ttm) | -7.58M |
| Shares Out | 39.98M |
| EPS (ttm) | -0.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 146,953 |
| Open | 0.590 |
| Previous Close | 0.582 |
| Day's Range | 0.569 - 0.600 |
| 52-Week Range | 0.490 - 3.130 |
| Beta | 3.14 |
| Analysts | Strong Buy |
| Price Target | 17.00 (+2,820.46%) |
| Earnings Date | May 7, 2026 |
About CRIS
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with r... [Read more]
Financial Performance
In 2025, Curis's revenue was $9.44 million, a decrease of -13.43% compared to the previous year's $10.91 million. Losses were -$7.58 million, -82.53% less than in 2024.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for CRIS stock is "Strong Buy." The 12-month stock price target is $17.0, which is an increase of 2,820.46% from the latest price.
News
Curis Earnings Call Transcript: Q4 2025
Q4 2025 saw a swing to net income due to a one-time gain from the Erivedge sale, with R&D and G&A expenses down year-over-year. PCNSL and CLL studies are prioritized, with initial CLL data expected at ASH 2026 and operations funded into H2 2027.
Curis Provides Fourth Quarter 2025 Business Update
Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass.
Curis Transcript: EGM 2026
Four key proposals—including increasing authorized shares, approving stock conversions and warrants, and adopting a new incentive plan—were presented and all passed by majority vote. Final results will be filed in a Form 8-K.
Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026
LEXINGTON, Mass., March 12, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and ...
Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
Led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners, LLC, and The Red Hook Fund, LP LEXINGTON, Mass., Jan. 9, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology ...
Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
LEXINGTON, Mass., Jan. 7, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FL...
Curis Provides Updated Data from its Frontline AML Triplet Study
5 of 8 patients (62.5%) achieved Undetectable MRD (uMRD) LEXINGTON, Mass. , Dec. 9, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (...
Curis to Present at Upcoming 30th Annual SNO Meeting
LEXINGTON, Mass. , Nov. 14, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi...
Curis Earnings Call Transcript: Q3 2025
Steady progress in lymphoma, CLL, and AML studies with promising early data and regulatory engagement. Net loss narrowed year-over-year, expenses declined, and cash runway extends into 2026, though additional capital will be sought before year-end.
Curis Provides Third Quarter 2025 Business Update
Management to host conference call and webcast today at 4:30 p.m. ET LEXINGTON, Mass.
Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025
LEXINGTON, Mass. , Oct. 30, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi...
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
LEXINGTON, Mass. , Oct. 3, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhib...
Curis Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Emavusertib, a first-in-class IRAK4 inhibitor, shows strong proof-of-concept in PCNSL and AML, outperforming standard therapies and offering a favorable safety profile. Expansion into CLL, other NHL subtypes, and solid tumors is planned, with pivotal studies and new data expected soon.
Curis Transcript: Cantor Global Healthcare Conference 2025
The company is advancing a pivotal IRAK4/FLT3 inhibitor in PCNSL with strong early efficacy, aiming for accelerated approval and planning a confirmatory trial. Expansion into CLL and AML is underway, with a focus on combination therapies to improve response rates and enable time-limited treatment.
Curis to Present at Upcoming Healthcare Conferences in September
LEXINGTON, Mass. , Sept. 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi...
Curis Earnings Call Transcript: Q2 2025
Emavusertib clinical programs advanced across PCNSL, CLL, AML, and MDS, with strong engagement from KOLs and promising early efficacy data. Net loss and expenses declined year-over-year, and recent financing extends the cash runway into Q1 2026.
Curis Provides Second Quarter 2025 Business Update
Management to host conference call and webcast today at 8:30 a.m. ET LEXINGTON, Mass.
Curis to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2025
LEXINGTON, Mass. , July 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi...
Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement
LEXINGTON, Mass. , July 2, 2025 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule I...
Curis Earnings Call Transcript: Q1 2025
Q1 2025 saw improved financials, strong clinical progress in PCNSL and AML, and the addition of Dr. Hamdy as CMO. Emavusertib showed promising efficacy, and cash runway extends into Q4 2025.
Curis Provides First Quarter 2025 Business Update
Curis strengthens executive team with the appointment of industry veteran Dr. Ahmed Hamdy as Chief Medical Officer Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass.
Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025
LEXINGTON, Mass. , April 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inh...
Curis Transcript: Jones Healthcare and Technology Innovation Conference 2025
The IRAK4 program is advancing in PCNSL with a pivotal trial enrolling 30-40 more patients over 12-18 months, supported by strong mechanistic rationale and early efficacy signals. Expansion to other NHL indications and AML is planned, with key data updates expected at major conferences.
Curis to Present at Upcoming Healthcare Conference in April
LEXINGTON, Mass. , April 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi...
Curis Earnings Call Transcript: Q4 2024
Significant clinical and regulatory progress was made in NHL and AML, with emavusertib showing strong efficacy and receiving orphan drug designation. Financials improved year-over-year, and recent equity offerings extended the cash runway into Q4 2025.